Biohaven completes enrollment in Phase 3 clinical trial for Multiple System Atrophy
Biohaven Pharmaceutical Holding Company Ltd. (BHVN) reported that it successfully met its enrollment targets for the M-STAR study. The trial investigates Verdiperstat as a treatment for multiple system atrophy. The drug candidate has been given Orphan Drug designation by the FDA. It is also in Fast Track pathway of the regulatory body. Additionally, European Medicines Agency has also given Orphan Drug designation to Verdiperstat.
M-STAR is a Phase 3 randomized, double-blind, placebo-controlled clinical trial. It aims to assess the safety and